Managers / Q2 2020 · view latest →
Corriente Advisors, LLC
CIK 0001406718 · 1401 FOCH ST, SUITE 100, FORT WORTH, TX, 76107 · 8178700400
Summary
Corriente Advisors, LLC reported $154M in U.S.-listed holdings across 16 positions for Q2 2020.
The portfolio is heavily concentrated: Maxar Technologies alone accounts for 22.1% of reported value.
Compared with Q1 2020, the fund opened 10 new positions and exited 5.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 88.3% · $136M
- Other · 11.3% · $17M
- REIT · 0.3% · $525,000
Quarter-over-Quarter Changes full breakdown →
vs Q1 2020 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| SONOSONOS INC | NEW | +1.57M | 1.57M | +$23M | $23M |
| REPLREPLIMUNE GROUP INC | NEW | +485.0K | 485.0K | +$12M | $12M |
| QUREUNIQURE NV | NEW | +180.0K | 180.0K | +$8M | $8M |
| OCULOCULAR THERAPEUTIX INC | NEW | +720.0K | 720.0K | +$6M | $6M |
| CLDXCELLDEX THERAPEUTICS INC NEW | NEW | +460.0K | 460.0K | +$6M | $6M |
| ARWRARROWHEAD PHARMACEUTICALS IN | NEW | +40.0K | 40.0K | +$2M | $2M |
| DMACDIAMEDICA THERAPEUTICS INC | NEW | +201.2K | 201.2K | +$1M | $1M |
| PAASPAN AMERN SILVER CORP | NEW | +30.0K | 30.0K | +$912,000 | $912,000 |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q2 2020
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | MAXAR TECHNOLOGIES INC | COM | 22.11% | $34M | 1.90M |
| 2 | REATA PHARMACEUTICALS INC | CL A | 14.91% | $23M | 147.5K |
| 3 | SONOSONOS INChistory → | COM | 14.88% | $23M | 1.57M |
| 4 | APTOSE BIOSCIENCES INC | COM NEW | 11.33% | $17M | 2.77M |
| 5 | CUE BIOPHARMA INC | COM | 10.48% | $16M | 660.0K |
| 6 | REPLREPLIMUNE GROUP INChistory → | COM | 7.81% | $12M | 485.0K |
| 7 | QUREUNIQURE NVhistory → | SHS | 5.26% | $8M | 180.0K |
| 8 | OCULOCULAR THERAPEUTIX INChistory → | COM | 3.89% | $6M | 720.0K |
| 9 | CLDXCELLDEX THERAPEUTICS INC NEWhistory → | COM NEW | 3.87% | $6M | 460.0K |
| 10 | TSLATESLA INChistory → | COM | 1.40% | $2M | 2.0K |
| 11 | ARWRARROWHEAD PHARMACEUTICALS INhistory → | COM | 1.12% | $2M | 40.0K |
| 12 | DMACDIAMEDICA THERAPEUTICS INC | COM NEW | 0.90% | $1M | 201.2K |
| 13 | PAASPAN AMERN SILVER CORP | COM | 0.59% | $912,000 | 30.0K |
| 14 | CRDFCARDIFF ONCOLOGY INC | COM | 0.56% | $869,000 | 173.4K |
| 15 | PIERIS PHARMACEUTICALS INC | COM | 0.54% | $837,000 | 270.0K |
| 16 | RWTREDWOOD TR INC | COM | 0.34% | $525,000 | 75.0K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q4 2023 | $10M | 3 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | Under review | 7 | Nov 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $10,872 | 2 | Aug 9, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $976,400 | 2 | May 10, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $0 | 1 | Feb 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $90M | 5 | Nov 15, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $237M | 5 | Aug 16, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $268M | 5 | May 16, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $12M | 3 | Feb 15, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $52M | 8 | Nov 15, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $185M | 15 | Aug 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $272M | 10 | May 18, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $420M | 19 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $197M | 16 | Nov 3, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $154M | 16 | Aug 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $93M | 11 | May 18, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $186M | 17 | Feb 14, 2020 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.